The first-in-class pulmonary arterial hypertension drug sotatercept was approved in March 2024 by the Food and Drug Administration (FDA) in the USA and the approval of the European Medicines Agency (EMA) is expected in the next few months. The UK Pulmonary Hypertension Association, PHA UK, has put together a short video, with its Chair Dr Iain Armstrong, to explain what happens next and what will be considered when it comes to making decisions for the UK.
Watch the video at this link on the PHA UK YouTube channel.
Read our article about the FDA approval at this link and the recommendation of the Committee for Human Medicinal Products (CHMP) of the EMA here